Sound waves may shield heart attack survivors from deadly rhythm problems
NCT ID NCT07587294
First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This study tests a new use of low-intensity focused ultrasound (LIFU) to calm nerve signals that can trigger dangerous heart rhythms after a heart attack. About 100 adults who recently had a severe heart attack will receive either real or fake ultrasound sessions during and for a week after their emergency heart procedure. Researchers will monitor heart rhythms, inflammation, and heart function to see if this gentle sound-wave treatment is safe and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 18 and 80 years (including 18 and 80 years); gender is not restricted; 2. Agree to be randomly assigned to a treatment strategy and be able to undergo follow-up as required; 3. Patients with a clinical diagnosis of acute ST-segment elevation myocardial infarction; 4. Presented within 12 hours of symptom onset and underwent PCI; 5. Killip functional class I-III; 6. Agree to participate in this study and voluntarily sign the informed consent form. Exclusion Criteria: 1. Patients with a history of myocardial infarction; 2. Patients with a history of cardiac pacemaker or implantable cardioverter-defibrillator (ICD) implantation; 3. Patients with severe bradycardia or high-degree atrioventricular block; 4. Patients with severe heart failure (left ventricular ejection fraction \<30%); 5. Patients with cardiogenic shock (Killip Class IV); 6. Patients admitted with frequent ventricular fibrillation or cardiac arrest; 7. Patients with a history of malignant hematological disorders or renal failure (estimated eGFR \<30 ml/min); 8. Patients with skin lesions, infections, or benign or malignant tumors in the left neck; 9. Pregnant or breastfeeding women, or women planning to become pregnant during the study; 10. Patients with severe cognitive impairment, psychiatric disorders, epilepsy, etc.; 11. Patients with concurrent malignant tumors or diseases of vital organs; 12. Patients with active systemic infections; 13. Patients who have participated in other drug or medical device clinical trials within the past 3 months; 14. Patients who are unable or unwilling to provide informed consent; 15. Patients deemed unsuitable for participation in this clinical trial by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute ST-segment elevation myocardial infarction (patients undergoing emergency pci) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Huangshi Central Hospital
NOT_YET_RECRUITINGHuangshi, Hubei, 430060, China
-
Jingzhou Central Hospital
NOT_YET_RECRUITINGJingzhou, Hubei, 430060, China
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, Hubei, 430060, China
-
Shiyan Taihe Hospital
NOT_YET_RECRUITINGShiyan, Hubei, 430060, China
-
Wuhan Central Hospital
NOT_YET_RECRUITINGWuhan, Hubei, 430060, China
-
Wuhan Third Hospital
NOT_YET_RECRUITINGWuhan, Hubei, 430060, China
-
Xiangyang Central Hospital
NOT_YET_RECRUITINGXiangyang, Hubei, 430060, China